Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J. Nastoupil, Frederick L. Locke, Michael D. Jain et al.|Journal of Clinical Oncology|2020Cited by 782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomasQing Deng, Michael R. Green, Neeraj Jain et al.|Nature Medicine|2020Cited by 593
Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experienceYasuhiro Oki, Jason R. Westin, Mansoor Noorani et al.|British Journal of Haematology|2014Cited by 364
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialNathan Fowler, Sattva S. Neelapu, R. Eric Davis et al.|The Lancet Oncology|2014Cited by 263
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Neeraj Saini et al.|Nature Medicine|2023Cited by 226